Zymeworks to acquire Theravance Biopharma in all-cash deal for $17 per share (~$929 m)

 

• Deal adds the YUPELRI COPD franchise to Zymeworks, along with significant royalty and tax assets.
• Transaction structure includes OMERS-backed non-recourse financing as part of the acquisition funding package.

https://finviz.com/stock?t=ZYME&p=d